Usher Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Usher syndrome is a group of inherited disorders characterized by dual sensory impairment of the auditory and visual systems. It is the most common cause of combined sight and hearing loss, accounting for more than half of deaf-blindness cases. Nine causative genes have been identified and confirmed responsible for the syndrome when mutated, including MYO7A, USH1C, CDH23, PCDH15, and USH1G for Usher type 1; USH2A, ADGRV1, and WHRN for Usher type 2; and CLRN1 for Usher type 3. Usher syndrome is clinically and genetically heterogeneous and is divided into three distinct clinical subtypes: Usher 1, Usher 2, and Usher 3. Usher 1 is the most severe subtype, in which patients exhibit severe to profound bilateral congenital sensorineural hearing loss, most frequently non-progressive, with vestibular areflexia. It accounts for approximately 25-44% of all Usher syndrome cases. Usher 2 represents over half of all cases. Sensorineural hearing loss is typically described as sloping, mild to moderate in the low frequencies, and severe to profound in the high frequencies. Infants are usually detected through the newborn hearing screen; however, if unavailable, detection can be overlooked till the end of the first decade of life. Usher 3 is rare in most populations, accounting for approximately 2-4% of all cases. The audiovestibular features are the most variable of the Usher subtypes. Hearing loss is the post-lingual onset, usually detected in the first decade of life, although onset can be delayed until adulthood. It is typical of a progressive nature, with audiograms showing high frequencies that are more affected or have a U-shaped configuration.
• The Usher syndrome is the most common cause of deaf–blindness worldwide, with a prevalence of between 4 and 17 in 100000 in the USA.

Thelansis’s “Usher Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Usher Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Usher Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Usher Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Usher Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033